St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
DICER1 syndrome is a genetic disorder that makes a person more likely to develop certain types of tumors. The tumors can be both benign (non-cancerous) and malignant (cancerous). Not everyone with DICER1 syndrome will develop a tumor.
Children with this syndrome can develop 1 or more tumors in these areas:
In babies and young children with DICER1 syndrome, the most common type of tumor appears in the lung. It is known as pleuropulmonary blastoma (PPB).
Children and young people with DICER1 syndrome have an increased risk of developing:
The exact risks for developing these or other tumors in DICER1 syndrome are not known.
DICER1 syndrome is caused by changes in a gene known as DICER1. Genes carry important information that tells our body’s cells how to function. In ways that are not well understood, DICER1 aids in preventing tumors.
Most cells of the body carry 2 working copies of the DICER1 gene in their cells. One is inherited from the mother and 1 from the father. Cells from people with DICER1 syndrome carry 1 working DICER1 gene copy and 1 copy that is altered. This change causes the gene to not work properly and is called a mutation.
Most people with DICER1 syndrome inherit it from a parent who also has the syndrome. But some people with DICER1 syndrome may have a new DICER1 gene mutation (change) that did not come from a parent. In these cases, the DICER1 mutation is new in these people, and they are the first in their families to have DICER1 syndrome.
No matter how it comes about, everyone with DICER1 syndrome has up to a 50% (1 in 2) chance of passing it on to their children.
Over time, the working copy of DICER1 can change within some of the cells. When both copies of the gene are changed, DICER1 tumors can develop. That is why people with DICER1 syndrome have a higher risk of developing 1 or more tumors.
A health care provider may suspect that your child has DICER1 syndrome after studying their medical and family cancer history.
This information helps the health care provider and the genetic counselor know if:
Your provider or genetics counselor may suggest DICER1 genetic testing if they suspect DICER1 syndrome. Learn more about types of genetic tests.
A blood sample is sent to a genetic testing lab. The lab runs genetic tests that look for changes in the DICER1 gene.
If your child has a DICER1 mutation, a genetic counselor will:
Parents may choose to do prenatal testing to find out if a pregnancy is affected with a known DICER1 mutation. Testing may take place either before pregnancy occurs or during pregnancy.
You should work with a genetic counselor to review the pros and cons of the test. The genetic counselor can also help you prepare for the test results.
Testing before pregnancy is called preimplantation genetic testing (PGT). This special type of genetic testing is done along with in vitro fertilization (IVF). PGT tests embryos for a known DICER1 mutation before a provider places the embryo into the uterus.
Testing during pregnancy can help providers see if a pregnancy has a known DICER1 mutation. A doctor gathers cells from the pregnancy in 1 of 2 ways:
After tissue collection, the lab checks the sample for the DICER1 mutation. Both tests carry minor risks. Discuss the risks with an experienced health care provider or a genetic counselor.
Take time to think carefully about the benefits and risks of genetic testing. Speak with a genetic counselor before testing. If you decide to get tested, talk with your health care provider or a genetic counselor about your results so you can understand what they mean.
Sometimes, children or adults with DICER1 syndrome feel sad, anxious, or angry after getting their test results. Parents may feel guilty if they pass the DICER1 gene mutation to 1 or more of their children.
People with a DICER1 gene mutation may also have trouble getting disability or life insurance. Read more about genetic discrimination.
There is no treatment for DICER1 syndrome. Instead, people with the syndrome should be monitored and have follow-up with a doctor who knows the condition well.
Children with DICER1 syndrome need regular screenings to detect tumors as early as possible. The goal of screening is to find and treat tumors early for the best outcome. Recommended screenings may change over time as doctors learn more about DICER1 syndrome.
Screening tests may include:
People with DICER1 syndrome should watch closely for signs and symptoms that could signal cancer. Seek medical help if anything unusual appears.
Children with DICER1 syndrome have a higher risk of cancer. They should monitor their health and adopt healthy habits. It is important to continue to have regular physical checkups and screenings. That way, any cancer can be found early at the most treatable stage.
People with DICER1 syndrome should watch closely for general signs and symptoms that could signal cancer:
Seek medical help if anything unusual appears.
Habits that will help you maintain a healthy lifestyle include:
The St. Jude Cancer Predisposition Program is dedicated to diagnosing and screening children with a genetic predisposition for cancer. Our program offers the best clinical care possible. We engage in cutting-edge research to gain more information about genetic disorders and cancer, and to improve care and treatment for patients who are affected by these conditions. Learn more about the Division of Cancer Predisposition at St. Jude.
Our genetic counselors, clinicians, genetics nurse practitioners, and research assistants work together to provide patients with:
DICER1 syndrome increases your child’s risk for many types of cancer.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults who have cancers associated with DICER1 syndrome. See diseases treated at St. Jude.
Learn more about clinical research at St. Jude.
Study goal:
To learn more about participants beliefs, attitudes, and questions about gene therapy to help make web-based resources to share information. This could help patients make treatment decisions.
Age:
18 to 35 years old with rare genetic diseases
Study goal:
The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.
Study goal:
To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators
Study goal:
1) Test each patient for hundreds of gene variations that might be important for drug use. All of the gene test results will be in the research laboratory, but as time goes on, the study will evaluate scientific evidence and selectively move test results for a few genes into the medical record if the evidence strongly shows that the result can help in better prescribing of drugs for patients; 2) Estimate how often pharmacogenetic test results are moved from research tests into a patient’s medical record; 3) Use methods to choose which of these tests should be put in the medical record; 4) Use computer-based tools in the electronic medical record to help doctors use gene test results when prescribing drugs; 5) Share feelings and concerns of patients and their families about gene test information being put in their medical record.
Study goal:
The main purpose of this trial is to learn about the genetic causes of cancer.
Age:
Younger than 50 years old
Study goal:
To collect data about how Friedreich’s ataxia progresses over time and affects the daily life of patients.
Age:
Any
Study goal:
To find out how much patients with hemophilia B, their caregivers, and health care workers know about gene therapy for this disease, and how they feel about gene therapy. This will help us better educate patients and caregivers about gene therapy for hemophilia B.
Age:
12 years and older
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
If you have questions about the Genetic Predisposition Clinic and care for DICER1 syndrome, email our team at GPTeam@stjude.org.